Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report.
Chronic graft-versus-host disease (cGVHD) is a frequent complication of allogenic bone marrow transplantation. Even with aggressive treatment, cGVHD is associated with a significant degree of morbidity and mortality. cGVHD resembles autoimmune disorder, particularly systemic sclerosis (SSc). Sarpogrelate hydrochloride (SH) is an antagonist of the 5-hydroxytryptamine2A (5HT2A) receptor and has been reported to be effective in the treatment of systemic sclerosis (SSc) patients with Raynaud phenomenon. We used SH to treat a cGVHD patient, and we measured plasma PDGF and total TGF-beta levels. After SH treatment, his plasma PDGF and total TGF-beta levels decreased, and he noticed improvement in his skin pigmentation. In the present case, SH may have improved the skin lesion by inhibiting the synthesis of PDGF and TGF-beta.
Hayashi
Tomoe
T
Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan. tomoe11@nifty.com
Morishita
Eriko
E
Ontachi
Yasuo
Y
Yamazaki
Masahide
M
Asakura
Hidesaku
H
Yoshida
Takashi
T
Nakao
Shinji
S
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002908:Chronic Disease; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D017479:Receptors, Platelet-Derived Growth Factor / Q000097:blood / Q000187:drug effects; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013386:Succinates / Q000494:pharmacology* / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000097:blood / Q000187:drug effects
D012702:Serotonin Antagonists; D013386:Succinates; D016212:Transforming Growth Factor beta; C064294:sarpogrelate; D017479:Receptors, Platelet-Derived Growth Factor